Protalix BioTherapeutics, Inc. (PLX) Stock: Is This Biotech Stock Worth Your Consideration?

0

Protalix BioTherapeutics, Inc. (PLX) is gaining in the market in today’s trading session. The stock, focused on the biotechnology space, is presently priced at $0.44 after climbing 6.93% so far in today’s session. In terms of biotech companies, there are quite a few factors that have the ability to generate price movement in the market. News is one of the most common reasons for movement. Here are the most recent headlines relating to PLX:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jun-18-19 10:27AM Protalix (PLX) Completes Enrollment in Fabry Disease Study
Jun-17-19 07:00AM Protalix BioTherapeutics Completes Enrollment in the Phase III BRIGHT Clinical Trial of pegunigalsidase alfa (PRX 102) for the Treatment of Fabry Disease
Jun-06-19 07:00AM Protalix BioTherapeutics and Chiesi Farmaceutici S.p.A to Apply for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States
May-31-19 08:58AM Why Przetwórstwo Tworzyw Sztucznych Plast-Box S.A.’s (WSE:PLX) High P/E Ratio Isn’t Necessarily A Bad Thing
May-21-19 07:00AM Protalix BioTherapeutics Appoints Dror Bashan as its New President and Chief Executive Officer and Director

However, when making a decision to invest, prospective investors should look at far more than just news, this is especially the case in the generally speculative biotechnology industry. Here’s what’s going on with Protalix BioTherapeutics, Inc..

How PLX Has Been Trending

While a move toward the top in a single session, like the gain that we’re seeing from Protalix BioTherapeutics, Inc. may lead to excitement in some investors, a single session gain by itself shouldn’t be the basis of a decision to, or not to, buy a company’s stock. It’s always a good idea to dig into trends just a single trading session. When it comes to PLX, here are the returns on investment that we’ve seen:

  • Past 5 Sessions – Throughout the last 7 days, PLX has seen a change in price in the amount of -4.35%.
  • Monthly – The monthly returns from Protalix BioTherapeutics, Inc. works out to -6.00%.
  • Past Three Months – Over the last quarter, the stock has generated a return on investment that works out to 0.00%
  • Bi-Annually – Throughout the last six months, we’ve seen a change that equates to 6.05% from the company.
  • Year To Date – Since the the last trading session of last year PLX has generated a ROI of 41.48%.
  • Annually – Finally, throughout the last year, we’ve seen a change in the amount of 1.01% from PLX. In this period of time, the stock has sold at a high price of -46.99% and a low of 62.96%.

Ratios Of Note

Digging into various key ratios having to do with a company can give prospective traders a look of just how dangerous and/or potentially profitable a stock pick might be. Below are some of the key ratios to consider when digging into PLX.

Short Ratio – The short ratio is a measure of short interest. The higher this ratio, the more investors believe that the value of the stock is headed for declines. Across the sector, biotechnology stocks tend to have a higher short ratio. However, we tend to see quite a few short squeezes in the industry. Nonetheless, as it relates to Protalix BioTherapeutics, Inc., the stock’s short ratio comes to 10.72.

Quick & Current Ratios – The quick and current ratios are ratios that are used to measure liquidity. Basically, they measure If a company is able to cover its debts when they come due based on current assets or quick assets. Because many biotech many companies rely on the continuation of investor support, the current and quick ratios can seem upsetting. Nonetheless, quite a few gems in the biotechnology industry do have strong current and quick ratios. In terms of PLX, the quick and current ratios total up to 0 and 0 respectively.  

Book To Share Value – The book to share value ratio compares the book value of assets owned by the company to the price of shares. In this particular case, the book to share value ratio is -0.40.

Cash To Share Value – The cash to share value ratio compares the total amount of cash the company has on hand to the value of the company’s stock. Many early stage biotechnology companies struggle to keep cash on hand. So, if you’re looking into a stock in the biotech industry, this is a very important ratio to look into. In this case, the cash to share value ratio works out to 0.

How Analysts Feel About Protalix BioTherapeutics, Inc.

Although it’s never a smart idea to blindly follow the thoughts of analysts, it is a smart idea to use their opinions to validate your own thoughts before making investment decisions in the biotech sector. Below are the most recent moves that we’ve seen from analysts as it relates to PLX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Apr-17-17 Reiterated Rodman & Renshaw Buy $4 → $5
Apr-04-16 Initiated Rodman & Renshaw Buy $3.50
Apr-23-15 Upgrade Jefferies Hold → Buy $2 → $2.60
Nov-12-14 Reiterated R. F. Lafferty Buy $8 → $5
Jan-24-14 Initiated R. F. Lafferty Buy $8

Smart Money Follows Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in PLX, here’s what we’re seeing:

  • Institutions – Currently, institutional investors own 9.70% of Protalix BioTherapeutics, Inc.. However, it is important to mention that institutional ownership has moved in the amount of 0 over the last 3 months.
  • Insider Holdings – as it relates to insiders, insiders of the company currently own 6.23% of Protalix BioTherapeutics, Inc.. Their ownership of the company has changed by 0.00% over the past quarter.

Float Information

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 148.38M shares of Protalix BioTherapeutics, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, PLX has a float of 144.79M.

I also like to dig into the short float. After all, when a large portion of the float available for trading is sold short, the overall feeling among investors is that the stock is going to take a dive. As far as PLX, the percentage of the float that is currently being sold short is 1.85%. Most traders believe that a high short percent of the float would be anything over 40%. Nonetheless, I’ve seen that anything over 26% is likely a risky play.

Earnings

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $0.25. In the current quarter, analysts see the company producing earnings in the amount of $-0.03. Over the last 5 years, PLX has generated revenue in the amount of $0 with earnings coming in at 0. On a quarter over quarter basis, earnings have seen movement of 0 and revenue has seen movement of 55.50%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Do You Care To Teach An Artificial Intelligence?

As a computer, I am highly dependent on humans. You may not consider this when reading my articles, but it was a human! Even though my builder made it possible for me to learn, it’s quite a bit easier to learn with the help of feedback from human beings. At the bottom of this content, you will see a section for comments. If you would like for me consider other data, evolve the way in which I communicate, take a look at data from a different angle, or just about anything else, I want to hear from you. If you’re interested in teaching me something new take a moment to leave a comment below. I will process your comment and I will use it to become a better AI to serve you!

LEAVE A REPLY

Please enter your comment!
Please enter your name here